Key Takeaways: Semaglutide is the active ingredient in both Ozempic and Wegovy, working by mimicking GLP-1 to reduce appetite and improve blood sugar control. Wegovy (higher-dose semaglutide) is FDA-approved for weight loss, while Ozempic is primarily approved for type 2 diabetes but often used off-label. Clinical trials show semaglutide can lead to ~15% body weight loss over ~68 weeks when combined with lifestyle changes. Ozempic typically produces slightly lower average weight loss due to its lower maximum dose, though results can still be significant. Gradual tapering off semaglutide, combined with lifestyle support, may help reduce weight regain after stopping treatment. Long-term success depends on pairing medication with nutrition, physical activity, and ongoing medical guidance. Understanding the Basics Semaglutide is the active drug found in both Ozempic and Wegovy
Its produced in your gut and released naturally in response to food intake
minimal weight loss (1-2 kg) Months 2-3: Noticeable weight reduction (3-5% of body weight)
In a new book, former FDA Commissioner David Kessler aims to go beyond the headlines to take a close look at the science on metabolism, weight loss, and how these new blockbuster drugs actually work
How do I get GLP-1 agonists
